ABSTRACT Fourteen patients with coronary artery disease and normal or near-normal left ventricular function were studied at rest and during atrial pacing until the occurrence of angina (12 patients) before and during infusion of dobutamine (3.80 + 0.45 ,ug/kg/min). At rest, during the infusion, three patients developed chest pain, mean ST segment depression increased from 0.02 to 0.08 mV (p < .001), and myocardial lactate extraction fell from + 17.5% to -1.4% (p < .05). These ischemic changes were associated with significant increases in arterial systolic pressure (134 to 149 mm Hg), heart rate (79 to 91 beats/min), coronary sinus flow (89 to 113 ml/min) and myocardial oxygen consumption (10.8 to 13.5 cc/min). In contrast, during atrial pacing, dobutamine did not reduce the pacing threshold or further increase myocardial oxygen consumption or ST segment changes; however, arterial mean and diastolic pressures were significantly lower with pacing during dobutamine infusion compared with control pacing. In the absence of heart failure, dobutamine in low doses can cause myocardial ischemia in patients with coronary artery disease. The absence of increased ischemia from dobutamine during pacing may reflect reversal of pacing-induced ventricular dysfunction. Circulation 68, No. 5, 1044-1050, 1983. BECAUSE of its relative lack of direct chronotropic and peripheral-vascular effects, dobutamine has become a popular inotropic agent for temporary support of cardiac patients with acute hypotension and lowoutput states, even when left ventricular function is only modestly impaired. Such patients frequently have had recent myocardial infarction or coronary artery surgery. Thus the effects of dobutamine on the balance between myocardial oxygen supply and demand in patients with coronary artery disease are of clinical importance. The purpose of our study was to evaluate the effects of dobutamine infusion on coronary hemodynamics and myocardial metabolism both at rest and during rapid atrial pacing in a group of patients with significant coronary disease who nevertheless had normal or only modest impairment of left ventricular function. Methods
BECAUSE of its relative lack of direct chronotropic and peripheral-vascular effects, dobutamine has become a popular inotropic agent for temporary support of cardiac patients with acute hypotension and lowoutput states, even when left ventricular function is only modestly impaired. Such patients frequently have had recent myocardial infarction or coronary artery surgery. Thus the effects of dobutamine on the balance between myocardial oxygen supply and demand in patients with coronary artery disease are of clinical importance. The purpose of our study was to evaluate the effects of dobutamine infusion on coronary hemodynamics and myocardial metabolism both at rest and during rapid atrial pacing in a group of patients with significant coronary disease who nevertheless had normal or only modest impairment of left ventricular function. Methods
Patients were selected for the study on the basis of a clinical significant coronary obstruction (>50% transluminal diameter) of at least one major coronary artery. Patients with unstable angina, significant left main coronary artery obstruction, myocardial infarction within the preceeding 6 weeks, severe heart failure (New York Heart Association class III or IV), or significant valvular heart disease were excluded. The study group was selected from the patients with angina pectoris who were referred to our cardiac catheterization laboratory for coronary angiography. The study group consisted of 14 patients who met all the inclusion criteria and who consented to participate in the study. The study was done 1 to 21 days (mean 8 days) after coronary angiography. f3-Adrenoreceptor blocking agents were discontinued for 48 hr and long-acting nitrates for 12 hr before the study. The dosage of discontinued /-blockers was 20 to 320 mg/day propranolol (mean 160 mg/day) in eight patients; six patients were not receiving l3-blockers before the study.
The study was performed in a specially equipped unit adjacent to the coronary care unit. The following procedure was used: Arterial systolic pressure (ASP), mean arterial pressure (MAP), and arterial diastolic pressure (ADP) were measured by a Statham 23 dB transducer after percutaneous insertion of a cannula into the radial or brachial artery. Coronary sinus flow (CSF) was measured by the continuous thermal dilution technique described by Ganz et al. In our laboratory, flows determined in vitro by this technique correlated well (r = .949) with directly measured flows of 50 to 450 ml/min delivered by an adjustable sigma motor pump into a circuit of synthetic tubing. After insertion of the thermistor catheter, its position was verified by injecting contrast material to outline the coronary sinus. To maintain a stable catheter position, the external thermistor was positioned well beyond the mouth of the coronary sinus. In this location, flow measurement and blood sampling are primar-ily reflections of the anterior-lateral left ventricular blood supply. Coronary vascular resistance (CVR) was calculated as the ratio of CSF to MAP. Atrial pacing was performed from the same catheter, which was equipped with bipolar pacing electrodes. A single electrocardiograph (ECG) lead, usually lead I, was monitored throughout the study. A standard 12-lead ECG was recorded before and during each pacing study. Three leads with the most pronounced ST segment depression, usually leads V4, V5, and V6, were recorded during the termination of pacing. Before initial atrial pacing, two sets of control measurements were obtained 10 min apart. These determinations resulted in no consistent differences in sequential measurements with time. CSF difference was 3.6 + 2.4 ml/min (mean ± SEM) (NS), MLEx was 11.6 ± 8.4% (NS), and (AO2 -CS02) was 1.2 +
1.4% (NS).
After control values were obtained, atrial pacing was begun at a rate of 110 beats/min and increased by 10 beats/ min every minute until the patient experienced significant chest discomfort or until a heart rate of 150 beats/min was reached. Pressure and flow measurements were obtained in duplicate at the peak pacing rate and pacing was then discontinued. To avoid baseline shift caused by atrial depolarization during pacing, the ST segment change was measured in the first three sinus beats after termination of pacing. A fall in the ST segment of 0.1 mV or greater was considered to represent electrocardiographic evidence of ischemia. In seven patients, atropine (0.5 to 1.0 mg) was given intravenously to achieve an adequate ventricular rate during atrial pacing. Fifteen minutes after the initial pacing study, control measurements were repeated, after which dobutamine infusion was started. After 15 min of dobutamine infusion, resting measurements were repeated and atrial pacing was performed as previously described.
In the first six patients studied, measurements were obtained at a single rate of dobutamine infusion ranging from 1.25 to 5.0 gg/kg/min. In the last eight patients, repeat measurements were obtained during progressively higher infusion rates, beginning at 1.5 to a maximum of 6.0 ug/kg/min. In these eight patients the results to be presented were obtained during the maximum dose of dobutamine for each patient. The control values used to assess the effects of dobutamine at rest were obtained just before begining the dobutamine infusion (i.e., 15 min after termination of the initial pacing study). Statistical analysis was performed with Student's t test for paired numerical data, and the difference between two mean values was considered significant at p < .05 with a two-tailed table.
Results
Clinical data (table 1). All patients were men, ranging in age from 49 to 70 years (mean 61). At diagnostic catheterization, left ventricular end-diastolic pressure ranged from 10 to 32 mm Hg (mean 17) and left ventricular ejection fraction ranged from 34% to 75% (mean 58%). All patients had significant obstruction of the left anterior descending coronary artery and 13 patients had involvement of the circumflex system. Seven patients had obstruction of a dominant right coronary vessel. Resting ECGs showed definite prior myocardial infarction in four patients, each of whom had abnormal ejection fraction (<50%).
Effects of dobutamine at rest (table 2) . ASP was significantly increased from 134 to 149 mm Hg (p < .01), while ADP and MAP were essentially unchanged, averaging 75 and 96 mm Hg, respectively, before dobutamine and 76 and 98 mm Hg during the infusion. Heart rate increased from 79 beats/min before to 91 beats/min during dobutamine infusion (p < .05). Heart rate (HR) increased from 81 to 91 beats/min with dobutamine in the subgroup of eight patients withdrawn from propranolol 48 hr before the study and from 76 to 90 beats/min in the subgroup of six patients not previously treated with propranolol. The product of HR x ASP (double product) increased from 10,400 to 13,200 mm Hg/beats/min (p < .01). CSF was also significantly increased during dobutamine from 89 to 1 3 ml/min (p < .01), while CVR fell from 1.30 mm Hg/ml/min before to 1.04 mm Hg/ml/min during the infusion (p < .05). MVO2 was significantly increased during dobutamine infusion from 10.8 to 13.5 cc/min (p < .01). MLEx averaged + 17.5% before dobutamine and was significantly reduced during the infusion, averaging -1.4% in 13 F  175  196  90  94  124  124  130  140  227  274  GR  120  110  80  70  86  80  150  150  180  165  w  148  126  98  80  114  100  132  112  195  141  S  135  135  95  86  110  106  140  152  189  205  V  174  190  112  100  135  126  150  150  261  285  A  136  138  98  82  120  101  150  150  204  207   D  140  117  88  70  106  88  140  150  196  176  E  142  116  102  78  102  78  150  150  213  174  1  170  145  120  106  132  118  144  130  245  189  GI  126  144  90  77  102  100  138  140  174  202  M  144  111  84  64  105  82  130  110  187  122  JA  148  155  88  75  118  100  120  120  178  186  Mean  146  140  95  82  113  100  140  138  204  194  SEM  5  8  3  4  4  5 
Discussion
Dobutamine is a potent inotropic agent with relatively less chronotropic, arrhythmogenic, or direct peripheral-vascular activity than older inotropic catecholamines Previous studies by our own group5 8 and others9' 10 have demonstratead that dobutamine consistently improves systemic hemodynamics and cardiac performance in patients with advanced chronic heart failure caused by ischemic heart disease.
Rarely has evidence of increased myocardial ischemia been noted in such patients during dobutamine infusion. Dobutamine has also been shown to improve hemodynamics after cardiac surgery"'-" and to improve left ventricular function in patients with acute myocardial infarctionl'4 without causing clinical, electrocardiographic, or enzymatic evidence of ischemia or increased necrosis.
This early experience has suggested that dobutamine might be an effective and safe agent for inotropic support of patients with coronary disease who have mild left ventricular dysfunction after acute myocardial infarction or during the first few hours after cardiac surgery. Although none of our patients had recent myocardial infarction or cardiac surgery, they all had angina rather than cardiac failure as the major clinical manifestation. The effect of dobutamine on coronary hemodynamics in such patients has not been studied. The patients selected for the present study all had significant coronary disease, but ventricular function was normal or only modestly impaired; none had clinical heart failure at the time of study. In such patients it is unlikely that a reduction in ventricular size and wall tension during dobutamine infusion, which might occur in patients with advanced congestive heart failure, would offset the increased myocardial oxygen demand associated with the chronotropic and inotropic effects of dobutamine. 8 Consistent with this expectation, our 14 patients showed a significant increase in resting MVO during dobutamine infusion, and although only three patients developed chest pain, the group as a whole demonstrated evidence of ischemia as indicated by a significant reduction in mean MLEx and an increase in ST segment depression. Although coronary blood flow increased substantially during dobutamine infusion, it is possible that this increase in flow was primarily to regions supplied by unobstructed vessels. Since only mean myocardial flow was measured in our study, a decrease in flow to regions supplied by obstructed vessels during dobutamine infusion would not be detected by this technique. The possibility of such a regional decrease in myocardial flow is supported by our recently reported observations of the development of new regional wall motion abnormalities detected by radionuclide imaging'9 and reversible thallium-20 1 perfusion defects20 during dobutamine infusion in similar patients with coronary artery disease. Likewise, Meyer et al. 2' showed that dobutamine infusion caused a heterogeneity of myocardial blood flow distribution in patients with severe coronary artery disease studied by xenon-133 myocardial scintigraphy. Although protection of ischemic myocardium during dobutamine infusion has been reported in experimental animals, 22' 23 there is reason to suspect that even low or modest doses of dobutamine may cause myocardial ischemia when given to some patients with significant coronary artery disease who are not in heart failure.
Our observations during atrial pacing were somewhat unexpected in that the addition of dobutamine infusion did not appear to alter the peak pacing rate achieved before the onset of angina, nor was MVO. different during the two pacing periods. The significantly lower MAP and ADP obtained during pacing with dobutamine infusion are likewise difficult to explain but may reflect an alteration in peripheral sympathetic tone in response to improved cardiac output during dobutamine infusion. These observations could be explained by the possibility that before dobutamine infusion, ischemia induced by atrial pacing resulted in a deterioration of left ventricular function with compensatory vasoconstriction, whereas during pacing and dobutamine ventricular function was preserved and peripheral resistance was relatively lower. This in turn could have resulted in reduced myocardial wall tension as compared with that during pacing without dobutamine. The reduction in myocardial wall tension would offset the direct inotropic effects of dobutamine on myocardial oxygen requirement. This would be consistent with our observation that mean MVO2 was actually lower during pacing with dobutamine than during pacing alone.
It must be noted, however, that a significant portion of the increase in MVO2 associated with dobutamine infusion is related to its chronotropic activity,24' 25 an effect that obviously played no role in our patients during atrial pacing.
Since neither cardiac output nor left ventricular filling pressure was measured in our study, our hypothesis for why dobutamine infusion did not increase MVO2 or reduce anginal threshold during atrial pacing in spite of its effects on resting parameters remains speculative. However, the hypothesis is consistent with prior observations that, in the vast majority of patients with severe chronic heart failure due to coronary disease, dobutamine infusion will improve left ventricular function and will not exacerbate myocardial ischemia.
Although ST segment depression was not further increased during pacing combined with dobutamine compared with pacing alone, there was a significant change in myocardial lactate metabolism toward lactate production. This change in lactate production could have been the result of increased ischemia; however, this seems unlikely in the absence of a reduced anginal threshold or an increase in MVO or ischemic ECG changes when pacing during dobutamine infusion is compared with control pacing. Alternatively, the apparent reduction in lactate utilization may have reflected a more rapid washout of lactate from ischemic myocardium or possibly a direct effect of catecholamines on substrate utilization unrelated to oxygen 26 
availability .2
Clinical implications. Our demonstration that low doses ofdobutamine can result in myocardial ischemia in patients with significant coronary obstructions who are not in heart failure should be considered when administering this drug to patients with known or suspected coronary artery disease. Dobutamine should be used with caution in the absence of significant heart failure or when left ventricular dysfunction might be the result of reversible ischemia.
